Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Paul Prather to Enzyme Inhibitors

This is a "connection" page, showing publications Paul Prather has written about Enzyme Inhibitors.

 
Connection Strength
  
 
 
0.120
  
  1. Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther. 2005 Aug; 314(2):868-75.
    View in: PubMed
    Score: 0.053
  2. Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica. 2019 Dec; 49(12):1388-1395.
    View in: PubMed
    Score: 0.035
  3. Crowe MS, Wilson CD, Leishman E, Prather PL, Bradshaw HB, Banks ML, Kinsey SG. The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice. Br J Pharmacol. 2017 Dec; 174(23):4523-4539.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.